MedPath

Calfactant

Generic Name
Calfactant
Brand Names
Infasurf
Drug Type
Small Molecule
CAS Number
183325-78-2
Unique Ingredient Identifier
Q4K217VGA9
Background

Calfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. It is an off-white suspension of an extract of natural surfactant from calf lungs suspended in 0.9% saline. Each milliliter of calfactant contains 35mg of phospholipids (including 26 mg phosphatidylcholine of which 16 mg is disaturated phosphatidylcholine) and 0.65mg of proteins including surfactant-associated proteins B and C.

Calfactant is approved for use in the United States of America. It is used to prevent or treat respiratory distress syndrome in premature infants with lung surfactant deficiency. Calfactant has been shown to decrease the incidence of respiratory distress syndrome, mortality due to respiratory distress syndrome, and air leaks associated with respiratory distress syndrome in clinical trials. It adsorbs to the air:fluid interface in the lungs and works to reduce surface tension, in a manner similar to endogenous pulmonary surfactant.

Indication

用于预防和治疗早产儿呼吸窘迫综合征（RDS）。

Associated Conditions
Respiratory Distress Syndrome
Clinical Trials
Related News

Cellectar Biosciences Advances Iopofosine I 131 and Radioconjugate Pipeline at Biotech Showcase

• Cellectar Biosciences plans to highlight its 2025 strategic initiatives at the Biotech Showcase during the JP Morgan Healthcare Conference. • The CLOVER-WaM study showed Iopofosine I 131 achieved an 83.6% overall response rate in relapsed/refractory Waldenstrom's Macroglobulinemia. • Cellectar is advancing radiotherapeutic assets, including CLR 121225 and CLR 121125, into Phase 1/2a solid tumor studies. • The company is working towards FDA accelerated approval and EMA Prime marketing authorization for Iopofosine I 131.

Bexion Pharmaceuticals Presents BXQ-350 Data in Metastatic Colorectal Cancer at ASCO GI 2025

• Bexion Pharmaceuticals will present a poster on BXQ-350 in combination with mFOLFOX7 and bevacizumab for metastatic colorectal cancer at the ASCO GI 2025. • BXQ-350 is a first-in-class biologic that modulates sphingolipid metabolism and has shown single-agent activity across multiple solid tumor types. • The Phase 1b/2 study evaluates BXQ-350 with standard of care in newly diagnosed metastatic colorectal cancer patients, with plans to proceed to a randomized, double-blinded, placebo-controlled phase. • Bexion is also exploring BXQ-350's potential in chemotherapy-induced peripheral neuropathy, addressing a significant unmet need.

Bexion Pharmaceuticals Completes Enrollment in Phase 1b/2 Trial of BXQ-350 for Metastatic Colorectal Cancer

• Bexion Pharmaceuticals has completed enrollment in the open-label phase of its ASIST trial, evaluating BXQ-350 in metastatic colorectal cancer. • The ASIST trial investigates BXQ-350 combined with mFOLFOX7 and bevacizumab as a first-line treatment for mCRC, potentially reducing chemotherapy-induced neuropathy. • BXQ-350, a first-in-class biologic, has demonstrated a robust safety profile and single-agent activity across various solid tumors in earlier phase 1 trials. • The study's primary endpoints include determining the recommended phase 2 dose, incidence of adverse events, and objective response rate, with an estimated completion in April 2029.

Alzheimer's Clinical Trial Update: New Data on Tau-Targeting Drugs and More

• Eisai presented Phase 1/2 data on E2814, an anti-tau drug, showing reduced levels of disease biomarkers in participants with mild to moderate genetic Alzheimer’s. • Roche terminated its agreement with UCB for beprenemab, an experimental tau-targeting antibody, after Phase 2 trial results showed it did not slow cognitive decline. • A Phase 2 trial of intranasal insulin and empagliflozin showed that insulin alone was associated with a small improvement in cognitive test performance in early Alzheimer’s patients.

CTAD 2024: Mixed Results for Alzheimer's Therapies Highlighted

• Eisai's E2814, an anti-tau drug, showed promise in reducing disease biomarkers in a Phase 1 trial involving participants with genetic Alzheimer's, warranting further studies. • Roche's trontinemab demonstrated effective amyloid reduction at high doses with a lower incidence of ARIA compared to other anti-amyloid antibodies in a Phase 1/2 trial. • UCB's beprenemab, a tau-targeting antibody, failed to slow cognitive decline in a Phase 2 trial, leading Roche to terminate their development and commercialization agreement. • Gene therapy LX001 from Lexeo Therapeutics showed early signs of success by increasing ApoE2 protein production and stabilizing amyloid levels in an ongoing Phase 1/2 study.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy